The Mediterranean and DASH diets, in particular, stand out due to their multidimensional effects on metabolic, vascular, and neuroinflammatory pathways
In a healthcare environment already defined by rising costs, the GLP-1 surge presents a critical challenge that requires a strategic, forward-thinking approach to plan design and cost containment
Key Takeaways In the Phase 3 TRIUMPH-1 trial (2026), retatrutide 12 mg produced an average 28.3% body-weight reduction at 80 weeks, with 45.3% of participants losing 30% or more ( New England Journal of Medicine / Eli Lilly, 2026 )
Despite hints of sex-specific effects, several gaps impede practice change
Read More about GenScript GLP-1 capability in the GenScript successful case section
Noom Launches Low Dose of Compounded Weight-Loss Drug For $119